Table 1.
Baseline characteristics of the intention-to-treat population.
| Characteristics | Once-a-week group (N = 250) | Once-every-3-weeks group (N = 260) |
|---|---|---|
| Sex | ||
| Male | 180 (72.0%) | 177 (68.1%) |
| Female | 70 (28.0%) | 83 (31.9%) |
| Median age, range (years) | 43 (21–65) | 44.5 (19–65) |
| Karnofsky scale | ||
| 90–100 | 219 (87.6%) | 222 (85.4%) |
| 70–80 | 31 (12.4%) | 38 (14.6%) |
| Histopathology | ||
| WHO II | 4 (1.6%) | 4 (1.5%) |
| WHO III | 246 (98.4%) | 256 (98.5%) |
| T classification | ||
| T1 | 2 (0.8%) | 1 (0.4%) |
| T2 | 9 (3.6%) | 8 (3.1%) |
| T3 | 210 (84.0%) | 213 (81.9%) |
| T4 | 29 (11.6%) | 38 (14.6%) |
| N classification | ||
| N0 | 29 (11.6%) | 35 (13.5%) |
| N1 | 112 (44.8%) | 112 (43.1%) |
| N2 | 81 (32.4%) | 84 (32.3%) |
| N3 | 28 (11.2%) | 29 (11.1%) |
| Staging | ||
| III | 197 (78.8%) | 199 (76.5%) |
| IVA | 25 (10.0%) | 32 (12.3%) |
| IVB | 28 (11.2%) | 29 (11.2%) |
| Pretreatment Epstein–Barr virus DNA test* | ||
| Negative | 95 (38.0%) | 90 (34.6%) |
| ∼4,000 copies per mL | 97 (38.8%) | 99 (38.1%) |
| >4,000 copies per mL | 54 (21.6%) | 69 (26.5%) |
| Missing | 4 (1.6%) | 2 (0.8%) |
| DNA (copies per mL), median (IQR) | 287 (0–3068) | 349 (0–4463) |
Note: Data are n (%) or median (range), unless otherwise stated. *The plasma Epstein–Barr virus DNA test was optional in this trial and was not done for all enrolled patients.